INTELLIA THERAPEUTICS INC

NTLA stock represents shares of Intellia Therapeutics, Inc., a clinical-stage biotechnology company. The ticker NTLA trades on the Nasdaq Global Select Market and gives investors exposure to the company's gene-editing research and development programs. Because the company is still developing its product candidates, NTLA is generally considered an early-stage biotech stock whose value is closely tied to progress in its clinical pipeline.

Valuation comparisons for NTLA depend heavily on the peer group used. Because Intellia is a clinical-stage biotech company, it may not have meaningful earnings or revenue multiples, so comparisons often focus on cash position, pipeline progress, and market capitalization relative to other gene-editing or biotechnology companies. For the latest comparative metrics, refer to the current valuation data shown on this page.

NTLA can be traded in U.S. pre-market and after-hours sessions, though liquidity is typically lower and spreads may be wider than during regular Nasdaq hours. Some brokers also offer overnight trading in eligible stocks. Availability, eligible order types, and session times vary by broker, so investors should check their platform for the specific extended-hours rules that apply to NTLA.

For a clinical-stage company like NTLA, financial analysis typically focuses on cash and cash equivalents, operating expenses, research and development spending, net loss, and how long the current cash runway may last. Investors often review quarterly filings and shareholder updates to track changes in these items alongside pipeline progress. The latest reported figures for NTLA are available on this page.

Key risks include clinical trial failures or delays, regulatory setbacks, manufacturing challenges, competition from other gene-editing and biotech companies, and substantial funding needs before any product is commercialized. NTLA may also face intellectual property disputes and share dilution if it raises additional capital. Because the company is not yet generating product revenue, its stock can be especially sensitive to news about its pipeline.

Reviewing NTLA generally involves examining the company's clinical pipeline and trial data, cash position and cash runway, quarterly financial statements, regulatory filings, and risk factors. It is also useful to check the current stock price, recent performance, and valuation metrics shown on this page. Because NTLA is a clinical-stage biotech, pipeline news and financing updates can be particularly important.